Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped down prior to trading on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva shares last traded at $3.7150, with a volume of 1,531,710 shares.

Analyst Upgrades and Downgrades

IVA has been the topic of several recent analyst reports. Guggenheim increased their price objective on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald started coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating for the company. Finally, Piper Sandler reissued an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Inventiva presently has a consensus rating of “Buy” and a consensus target price of $15.14.

Inventiva Stock Performance

The company has a debt-to-equity ratio of 0.90, a current ratio of 3.81 and a quick ratio of 3.16. The business has a fifty day simple moving average of $4.37 and a two-hundred day simple moving average of $4.69.

Inventiva (NASDAQ:IVA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million during the quarter. On average, equities analysts predict that Inventiva S.A. Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Engineers Gate Manager LP grew its position in shares of Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP purchased a new position in Inventiva during the first quarter valued at $1,111,000. Persistent Asset Partners Ltd purchased a new position in Inventiva during the fourth quarter valued at $603,000. NEXTBio Capital Management LP purchased a new position in Inventiva during the fourth quarter valued at $6,039,000. Finally, Eventide Asset Management LLC bought a new stake in Inventiva during the fourth quarter valued at about $1,155,000. 19.06% of the stock is currently owned by institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.